OraSure (OSUR) 10-Q 8 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Common Stock, Shares Outstanding		72,622,043
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 75,205	$ 116,762
Short-term investments	26,432	36,279
Accounts receivable, net of allowance for doubtful accounts of $4,176 and $3,418	61,306	45,323
Inventories	78,805	53,138
Prepaid expenses	5,844	7,939
Other current assets	32,140	28,990
Total current assets	279,732	288,431
Noncurrent Assets:
Property, plant and equipment, net	85,184	88,164
Operating right-of-use assets, net	15,769	9,056
Finance right-of-use assets, net	1,590	2,493
Intangible assets, net	11,919	14,343
Goodwill	34,476	40,279
Long-term investments		17,009
Other noncurrent assets	3,538	1,215
Total noncurrent assets	152,476	172,559
TOTAL ASSETS	432,208	460,990
Current Liabilities:
Accounts payable	40,370	28,024
Deferred revenue	2,536	2,936
Accrued expenses and other current liabilities	25,412	33,778
Finance lease liabilities	1,242	939
Operating lease liabilities	1,938	2,181
Acquisition-related contingent consideration obligation	199	206
Total current liabilities	71,697	68,064
Noncurrent Liabilities:
Finance lease liabilities	935	1,952
Operating lease liabilities	14,493	7,202
Acquisition-related contingent consideration obligation	117	354
Other noncurrent liabilities	525	651
Deferred income taxes	2,551	2,234
Total noncurrent liabilities	18,621	12,393
TOTAL LIABILITIES	90,318	80,457
Commitments and contingencies (Note 12)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 72,619 and 72,069 shares issued and outstanding	0	0
Additional paid-in capital	518,170	511,063
Accumulated other comprehensive loss	(22,331)	(10,077)
Accumulated deficit	(153,949)	(120,453)
Total stockholders' equity	341,890	380,533
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 432,208	$ 460,990

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 4,176	$ 3,418
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	72,619,000	72,069,000
Common stock, shares outstanding	72,619,000	72,069,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
NET REVENUES:
Total revenue	$ 116,463	$ 53,917	$ 264,401	$ 170,106
COST OF PRODUCTS AND SERVICES SOLD	70,271	32,449	166,353	79,639
Gross profit	46,192	21,468	98,048	90,467
OPERATING EXPENSES:
Research and development	9,757	8,596	27,238	25,270
Sales and marketing	13,474	13,886	37,875	33,836
General and administrative	15,527	12,499	52,262	33,680
Loss on impairment	6,559		17,101
Change in the estimated fair value of acquisition-related contingent consideration		(500)	(36)	(1,526)
Total operating expenses	45,317	34,481	134,440	91,260
Operating income (loss)	875	(13,013)	(36,392)	(793)
OTHER INCOME	3,255	100	4,520	429
Income (loss) before income taxes	4,130	(12,913)	(31,872)	(364)
INCOME TAX EXPENSE (BENEFIT)	(1,143)	2,102	1,624	12,241
NET INCOME (LOSS)	$ 5,273	$ (15,015)	$ (33,496)	$ (12,605)
INCOME (LOSS) PER SHARE:
Basic	$ 0.07	$ (0.21)	$ (0.46)	$ (0.18)
Diluted	$ 0.07	$ (0.21)	$ (0.46)	$ (0.18)
Weighted-average shares of common stock outstanding:
Basic	72,616	72,023	72,448	71,962
DILUTED	72,785	72,023	72,448	71,962
Products and Services [Member]
NET REVENUES:
Total revenue	$ 112,821	$ 53,229	$ 257,224	$ 165,549
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 3,642	$ 688	$ 7,177	$ 4,557

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 5,273	$ (15,015)	$ (33,496)	$ (12,605)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	(9,828)	(4,117)	(12,421)	(1,362)
Unrealized gain (loss) on marketable securities	11	(161)	167	(262)
COMPREHENSIVE LOSS	$ (4,544)	$ (19,293)	$ (45,750)	$ (14,229)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
OPERATING ACTIVITIES:
Net income (loss)			$ (33,496)	$ (12,605)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation			9,100	5,155
Depreciation and amortization			11,391	8,479
Loss on impairment	$ 6,559		17,101
Other non-cash amortization			411	664
Provision for doubtful accounts			974	1,228
Inventory reserve			977	2,908
Unrealized foreign currency gain			(396)	(319)
Interest expense on finance leases	19	$ 49	74	84
Deferred income taxes			542	(324)
Loss on disposal of fixed assets			729
Change in the estimated fair value of acquisition-related contingent consideration		(500)	(36)	(1,526)
Payment of acquisition-related contingent consideration				(142)
Changes in assets and liabilities
Accounts receivable			(19,152)	(2,102)
Inventories			(27,586)	(24,597)
Prepaid expenses and other assets			(5,990)	(1,942)
Accounts payable			16,246	2,790
Deferred revenue			(312)	(1,331)
Accrued expenses and other liabilities			233	982
Net cash used in operating activities			(29,190)	(22,598)
INVESTING ACTIVITIES:
Purchases of investments			(22,873)	(25,443)
Proceeds from maturities and redemptions of investments			47,415	53,745
Purchases of property and equipment	(2,641)	(4,579)	(28,081)	(27,508)
Purchase of property and equipment under government contracts	(4,902)		(38,705)
Proceeds from funding under government contract			37,756		$ 531
Other investing activities				(18)
Net cash (used in) provided by investing activities			(4,488)	776
FINANCING ACTIVITIES:
Cash payments for lease liabilities			(826)	(1,111)
Proceeds from exercise of stock options			15	247
Payment of acquisition-related contingent consideration			(208)	(264)
Repurchase of common stock			(2,008)	(1,924)
Net cash used in financing activities			(3,027)	(3,052)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH			(4,852)	(966)
NET DECREASE IN CASH AND CASH EQUIVALENTS			(41,557)	(25,840)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			116,762	160,802	160,802
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 75,205	$ 134,962	75,205	134,962	$ 116,762
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes			9,400	12,540
Non-cash investing and financing activities
Accrued property and equipment purchases			1,463	4,382
Accrued property and equipment purchases under government contracts			2,374
Unrealized gain (loss) on marketable securities			$ 167	$ (262)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation . The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results of operations expected for the full year. Summary of Significant Accounting Policies . There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that have had a material impact on the consolidated financial statements and related notes except as discussed herein. Investments . We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds purchased with maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. During the nine months ended September 30, 2022, we recognized a provision for expected credit losses for our available-for-sale securities of $ 56 . The following is a summary of our available-for-sale securities as of September 30, 2022 and December 31, 2021: Amortized Gross Gross Fair Value September 30, 2022 Guaranteed investment certificates $ 21,688 $ — $ — $ 21,688 Corporate bonds 5,011 — ( 267 ) 4,744 Total available-for-sale securities $ 26,699 $ — $ ( 267 ) $ 26,432 December 31, 2021 Guaranteed investment certificates $ 33,249 $ — $ — $ 33,249 Corporate bonds 20,473 — ( 434 ) 20,039 Total available-for-sale securities $ 53,722 $ — $ ( 434 ) $ 53,288 At September 30, 2022, maturities of our available-for-sale Less than one year $ 26,699 $ — $ ( 267 ) $ 26,432 Greater than one year $ — $ — $ — $ — Fair Value of Financial Instruments . As of September 30, 2022 and December 31, 2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale debt securities are measured as Level 2 instruments as of September 30, 2022 and December 31, 2021. Our available-for-sale guaranteed investment certificates are measured as Level 1 instruments as of September 30, 2022 and December 31, 2021. Included in cash and cash equivalents at September 30, 2022 and December 31, 2021, was $ 1,717 and $ 1,160 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of September 30, 2022 and December 31, 2021 was $ 1,599 and $ 1,763 , respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets. Property, Plant and Equipment . Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty years , while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years . Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of September 30, 2022 and December 31, 2021 was $ 68,626 and $ 61,157 , respectively. Intangible Assets . Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years . Accumulated amortization of intangible assets as of September 30, 2022 and December 31, 2021 was $ 29,943 and $ 30,412 , respectively. The decrease in intangible assets from $ 14,343 as of December 31, 2021 to $ 11,919 as of September 30, 2022 was due to $ 1,617 in amortization expense and foreign currency translation losses of $ 807 . Impairment of Long-Lived Assets . Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. We assess the recoverability of our long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. During the three months ended September 30, 2022, management determined several manufacturing lines and associated supporting assets will not be utilized due to changes in forecasted demand for the products the lines are intended to produce. As a result of this decision, we determined that the carrying values of the equipment is not recoverable and recorded an aggregate pre-tax asset impairment charge of $ 6,559 during the three months ended September 30, 2022 to write the assets down to their estimated fair values. This charge is reported within loss on impairment in the consolidated statement of operations. We estimated the fair value of the impaired long-lived assets using a market approach, which required us to estimate the value that would be received for the equipment in the most advantageous market for that equipment in an orderly transaction between market participants. Due to the extremely specialized nature of the manufacturing equipment and various market data points, the estimated fair value was not significant. Our fair value estimates were representative of Level 3 measurements within the fair value hierarchy due to the significant level of estimation involved and the lack of transparency as to the inputs used. Foreign Currency Translation . The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains resulting from foreign currency transactions that are included in other income in our consolidated statements of operations were $ 2,342 and $ 7 for the three months ended September 30, 2022 and 2021, respectively. Net foreign exchange gains (losses) were $ 2,396 and $( 371 ) f or the nine months ended September 30, 2022 and 2021 , respectively. Accumulated Other Comprehensive Loss . We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at September 30, 2022 consisted of $ 22,064 of currency translation adjustments and $ 267 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2021 consists of $ 9,643 of currency translation adjustments and $ 434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Recent Accounting Pronouncements . In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU were effective upon issuance and could be applied prospectively through December 31, 2022. The FASB issued a proposed amendment to the ASU in April 2022 which, if approved, will extend the date for prospective application to December 31, 2024. Management has evaluated this ASU and concluded that it will not have a material impact on the Company's Consolidated Financial Statements .

Government Capital Contracts

Government Capital Contracts	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Government Capital Contracts	2. Government Capital Contracts In September 2021, we entered into an agreement fo r $ 109,000 in funding from the U.S. Department of Defense (the “DOD”), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for our InteliSwab ® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. Funding will be paid to the Company based on achievement of milestones through March 2024 for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. In accordance with the milestone payment schedule, 15 % of the total will not be funded until the completion of the final equipment validation, which is scheduled to occur in late 2023 or early 2024. We began making payments to vendors for the capital project during the fourth quarter of 2021 and began receiving funds from the DOD in January 2022. Additionally, during 2021, we received $ 531 in funding from the Co mmonwealth of Pennsylvania, acting through the Department of Community and Economic Development, for the purchase of machinery and equipment as part of an expansion of manufacturing operations in Pennsylvania. All related purchases were completed in 2021.  Activity for these capital contracts is accounted for pursuant to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding earned in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows; and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows. Amounts earned in excess of our expected cost of the project for project management are recognized straight-line in other income over the term of the government contract. We recognized $ 561 and $ 1,684 of such income for the three and nine months ended September 30, 2022, respectively, which is reported as other income in our consolidated statement of operations. The balances corresponding to government contracts included in our consolidated balance sheet are as follows: September 30, 2022 December 31, 2021 Other current assets: Billed receivables $ 1,489 $ 9,913 Unbilled receivables 13,840 9,716 Total other current assets 15,329 19,629 Property, plant and equipment, net: Cost of assets, cumulative 50,200 11,495 Reduction for funding earned to date, not yet received ( 11,913 ) ( 10,964 ) Reduction for funding received to date ( 38,287 ) ( 531 ) Total property, plant and equipment, net — — Other non-current assets - unbilled receivables 2,489 — Accrued expenses and other current liabilities $ ( 404 ) $ ( 8,103 )

Inventories

Inventories	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	3. Inventories September 30, 2022 December 31, 2021 Raw materials $ 37,137 $ 33,168 Work in process 2,499 2,252 Finished goods 39,169 17,718 $ 78,805 $ 53,138

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	4. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive. The computations of basic and diluted earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net income (loss) $ 5,273 $ ( 15,015 ) $ ( 33,496 ) $ ( 12,605 ) Weighted-average shares of common stock outstanding: Basic 72,616 72,023 72,448 71,962 Dilutive effect of stock options, restricted stock, and performance stock units 169 — — — Diluted 72,785 72,023 72,448 71,962 Earnings (loss) per share: Basic $ 0.07 $ ( 0.21 ) $ ( 0.46 ) $ ( 0.18 ) Diluted $ 0.07 $ ( 0.21 ) $ ( 0.46 ) $ ( 0.18 ) For the three months ended September 30,2022, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 1,734 shares were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2022, and the three and nine months ended September 30, 2021, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 383 , 859 , and 847 shares, respectively, were excluded from the computation of diluted loss per share.

Revenues

Revenues	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues	5. Revenues Revenues by product line . The following table represents total net revenues by product line: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 COVID-19 $ 79,920 $ 13,930 $ 154,331 $ 54,147 Genomics 13,980 19,018 44,558 49,333 HIV 9,054 10,022 27,577 29,745 HCV 3,234 2,715 10,182 9,382 Substance abuse 2,595 2,674 7,786 7,265 Microbiome 1,761 1,693 5,583 5,888 Laboratory services 1,957 2,406 4,895 8,017 Other product and service revenues 320 771 2,312 1,772 Net product and services revenues 112,821 53,229 257,224 165,549 Royalty income 409 500 1,735 2,636 Other non-product revenues* 3,233 188 5,442 1,921 Other revenues 3,642 688 7,177 4,557 Net revenues $ 116,463 $ 53,917 $ 264,401 $ 170,106 * Other non-product revenues include funded research and development under our BARDA contracts and other grant revenues. Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 108,941 $ 42,969 $ 237,248 $ 139,669 Europe 2,207 2,411 8,929 10,288 Other regions 5,315 8,537 18,224 20,149 $ 116,463 $ 53,917 $ 264,401 $ 170,106 Customer and Vendor Concentrations . At September 30, 2022 , one non-commercial customer accounted for 47 % of our accounts receivable. No customers accounted for more than 10 % of our accounts receivable as of December 31, 2021 . One non-commercial customer accounted for 69 % and 53 % of net consolidated revenues for the three and nine months ended September 30, 2022 , respectively. One customer accounted for 14 % of net consolidated revenues for the three months ended September 30, 2021 . Another customer accounted for 10 % of net consolidated revenues for the nine months ended September 30, 2021. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. Deferred Revenue . We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2022 and December 31, 2021 includes customer prepayments of $ 1,762 and $ 1,843 , respectively. Deferred revenue as of September 30, 2022 and December 31, 2021 also include s $ 774 and $ 1,093 , respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	6. Goodwill The following table represents the changes in goodwill by operating segment for the nine months ended September 30, 2022: Diagnostics Molecular Solutions Balance as of January 1, 2022 $ 3,604 $ 36,675 Impairment ( 3,604 ) — Change related to foreign currency translation — ( 2,199 ) Balance as of September 30, 2022 $ — $ 34,476 During the second quarter of 2022, we determined that a triggering event occurred in relation to the depressed market price of the Company's common stock and corresponding significant decline in our market capitalization. As a result, we performed an interim goodwill impairment test and concluded that the carrying value of our Diagnostics reporting unit exceeded its estimated fair value and the goodwill balance for that segment was fully impaired. Thus, we recognized a pre-tax impairment charge of $ 3.6 million during the three months ended June 30, 2022, which is reported in loss on impairments in our condensed consolidated statement of operations. In the second quarter, we estimated fair values of both of our reporting units using a combined income-based approach and market-based approach. O ur income approach utilized projected future cash flows that were discounted at a rate of 22 % for the Diagnostic reporting unit and 20 % for the Molecular Solutions reporting unit based on a weighted-average cost of capital analysis that reflected current market conditions. The market comparable approach primarily considered earnings, revenue and other multiples of comparable companies and applied those multiples to certain key drivers of the reporting units. This market approach utilized a revenue multiple weighted by year for the Diagnostics reporting unit and both a revenue and EBITDA multiple for the Molecular Solutions reporting unit. We assigned a weight of 75 % to the results of our income-based approach and 25 % to the results from the market-based approach for estimation of the reporting units' fair value. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements. We perform an annual goodwill impairment assessment as of July 31 each year. Historically this involved a qualitative analysis that resulted in a conclusion that it was more likely than not that the fair value of our reporting units is greater than their carrying value. In 2022, as a result of the depressed market price of the Company's common stock and corresponding significant decline in our market capitalization, we performed a quantitative analysis by comparing the estimated fair values of our reporting units to their respective carrying values. Our quantitative goodwill impairment test assessment as of July 31, 2022 concluded that the carrying value of our Molecular Solutions reporting unit exceeded its estimated fair value and no impairment of the related goodwill exists. A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and other current liabilities September 30, December 31, Payroll and related benefits $ 11,263 $ 15,570 Commitment to purchase under government contract — 8,103 Professional fees 4,771 3,335 Sales tax payable 1,372 2,227 Other 8,006 4,543 $ 25,412 $ 33,778

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Lessee Disclosure [Abstract]
Leases	8. Leases We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of September 30, 2022, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 11 years , some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year . As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components. The components of lease expense are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost $ 842 $ 655 $ 2,352 $ 1,574 Variable and short-term lease cost 332 — 559 — Finance lease cost: Amortization of right-of use assets 343 571 1,034 910 Interest on lease liabilities 19 49 74 84 Total finance lease cost 362 620 1,108 994 Total lease cost $ 1,536 $ 1,275 $ 4,019 $ 2,568 Supplemental cash flow information related to leases is as follows: Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 3,659 $ 1,182 Operating cash flows from financing leases 74 84 Financing cash flows from financing leases 826 1,111 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations 9,038 45 Right-of-use assets obtained in exchange for finance lease obligations 117 2,746 Supplemental balance sheet information related to leases is as follows: September 30, 2022 December 31, 2021 Operating Leases Right-of-use assets $ 15,769 $ 9,056 Lease liabilities: Current lease liabilities 1,938 2,181 Non-current lease liabilities 14,493 7,202 Total operating lease liabilities $ 16,431 $ 9,383 Finance Leases Right-of-use assets $ 1,590 $ 2,493 Lease liabilities: Current lease liabilities 1,242 939 Non-current lease liabilities 935 1,952 Total finance lease liabilities $ 2,177 $ 2,891 Weighted Average Remaining Lease Term Weighted-average remaining lease term—operating leases 7.46 years 5.26 years Weighted-average remaining lease term—finance leases 1.59 years 2.21 years Weighted Average Discount Rate Weighted-average discount rate—operating leases 4.25 % 3.90 % Weighted-average discount rate—finance leases 3.45 % 3.57 % As of September 30, 2022, minimum lease payments by period are expected to be as follows: Finance Operating 2022 (excluding the nine months ended September 30, 2022) $ 373 $ 795 2023 1,125 2,043 2024 738 2,947 2025 18 2,583 2026 11 2,385 Thereafter — 8,800 Total minimum lease payments 2,265 19,553 Less: imputed interest ( 88 ) ( 3,122 ) Present value of lease liabilities $ 2,177 $ 16,431 On October 19, 2022, the Company entered into a termination agreement for a warehouse entered into on January 3, 2022, related to its 96,010 square foot facility in York, Pennsylvania. Pursuant to the terms of the termination agreement, the lease terminated, effective on October 31, 2022 . The Company is not required to pay a termination fee, and has been released from all further rent obligations under the lease, resulting in ongoing annual cash savings of approximately $ 735 . Termination will result in an operating right-of-use assets and lease liabilities reduction of $ 4,927 and $ 5,146 , respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021 Common Stock Additional Accumulated Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2021 72,069 $ — $ 511,063 $ ( 10,077 ) $ ( 120,453 ) $ 380,533 Common stock issued upon exercise of options 2 — 15 — — 15 Vesting of restricted stock and performance stock units 352 — — — — — Purchase and retirement of common shares ( 116 ) — ( 1,049 ) — — ( 1,049 ) Stock-based compensation — — 3,524 — — 3,524 Net loss — — — — ( 19,967 ) ( 19,967 ) Currency translation adjustments — — — 1,756 — 1,756 Unrealized gain on marketable securities — — — 74 — 74 Balance at March 31, 2022 72,307 $ — $ 513,553 $ ( 8,247 ) $ ( 140,420 ) $ 364,886 Common stock issued upon exercise of options — — — — — — Vesting of restricted stock and performance stock units 407 — — — — — Purchase and retirement of common shares ( 142 ) — ( 905 ) — — ( 905 ) Stock-based compensation — — 3,280 — — 3,280 Net loss — — — — ( 18,802 ) ( 18,802 ) Currency translation adjustments — — — ( 4,349 ) — ( 4,349 ) Unrealized gain on marketable securities — — — 82 — 82 Balance at June 30, 2022 72,572 $ — $ 515,928 $ ( 12,514 ) $ ( 159,222 ) $ 344,192 Common stock issued upon exercise of options — — — — — — Vesting of restricted stock and performance stock units 66 — — — — — Purchase and retirement of common shares ( 19 ) — ( 54 ) — — ( 54 ) Stock-based compensation — — 2,296 — — 2,296 Net income — — — — 5,273 5,273 Currency translation adjustments — — — ( 9,828 ) — ( 9,828 ) Unrealized loss on marketable securities — — — 11 — 11 Balance at September 30, 2022 72,619 $ — $ 518,170 $ ( 22,331 ) $ ( 153,949 ) $ 341,890 Common Stock Additional Accumulated Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2020 71,738 $ — $ 505,123 $ ( 9,097 ) $ ( 97,455 ) $ 398,571 Common stock issued upon exercise of options 11 — 92 — — 92 Vesting of restricted stock and performance stock units 318 — — — — Purchase and retirement of common shares ( 111 ) — ( 1,730 ) — — ( 1,730 ) Stock-based compensation — — 1,464 — — 1,464 Net income — — — — 3,774 3,774 Currency translation adjustments — — — 1,352 — 1,352 Unrealized gain on marketable securities — — — 21 — 21 Balance at March 31, 2021 71,956 $ — $ 504,949 $ ( 7,724 ) $ ( 93,681 ) $ 403,544 Common stock issued upon exercise of options 3 — 29 — — 29 Vesting of restricted stock and performance stock units 64 — — — — — Purchase and retirement of common shares ( 15 ) — ( 147 ) — — ( 147 ) Stock-based compensation — — 1,473 — — 1,473 Net loss — — — — ( 1,364 ) ( 1,364 ) Currency translation adjustments — — — 1,403 — 1,403 Unrealized loss on marketable securities — — — ( 122 ) — ( 122 ) Balance at June 30, 2021 72,008 $ — $ 506,304 $ ( 6,443 ) $ ( 95,045 ) $ 404,816 Common stock issued upon exercise of options 18 — 126 — — 126 Vesting of restricted stock and performance stock units 16 — — — — — Purchase and retirement of common shares ( 4 ) — ( 47 ) — — ( 47 ) Stock-based compensation — — 2,218 — — 2,218 Net loss — — — — ( 15,015 ) ( 15,015 ) Currency translation adjustments — — — ( 4,117 ) — ( 4,117 ) Unrealized loss on marketable securities — — — ( 161 ) — ( 161 ) Balance at September 30, 2021 72,038 $ — $ 508,601 $ ( 10,721 ) $ ( 110,060 ) $ 387,820 Stock-Based Awards We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market. Total compensation expense related to stock options for the nine months ended September 30, 2022 and 2021 was $ 1,213 and $ 793 , respectively. The following table summarizes the stock option activity for the nine months ended September 30, 2022: Options Outstanding on January 1, 2022 1,410 Granted 589 Exercised ( 2 ) Expired ( 20 ) Forfeited ( 173 ) Outstanding on September 30, 2022 1,804 Compensation expense of $ 7,047 and $ 2,891 related to restricted shares was recognized during the nine months ended September 30, 2022 and 2021, respectively. The following table summarizes time-vested restricted stock award and restricted stock unit activity for the nine months ended September 30, 2022: Units Issued and unvested, January 1, 2022 701 Granted 2,964 Vested ( 618 ) Forfeited ( 270 ) Issued and unvested, September 30, 2022 2,777 We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain employed for three years from the grant date. If the one-year target is achieved, the PSUs will then vest three years from grant date. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Compensation expense of $ 840 and $ 1,471 related to PSUs was recognized during the nine months ended September 30, 2022 and 2021, respectively. The following table summarizes the PSU activity for the nine months ended September 30, 2022: Units Issued and unvested, January 1, 2022 622 Granted (1) 532 Performance adjustment (2) 36 Vested ( 207 ) Forfeited ( 200 ) Issued and unvested, September 30, 2022 783 (1) Grant activity for all PSUs disclosed at target (2) Reflects the performance adjustment based on actual performance measured at the end of the performance period Stock Repurchase Program On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $ 25,000 of our outstanding common shares. No shares were purchased and retired during the nine months ended September 30, 2022 and 2021.

Transition Costs

Transition Costs	9 Months Ended
	Sep. 30, 2022
Transition Costs [Abstract]
Transition Costs	10. Transition costs On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s former President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a transition agreement ("Transition Agreement") providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Dr. Tang’s service to the Company in all capacities ended on March 31, 2022. Pursuant to the Transition Agreement, Dr. Tang received severance of $ 1,569 , which was accrued in the consolidated financial statements at December 31, 2021 and paid in April 2022. Additionally, in accordance with his Transition Agreement, certain of his unvested time-vesting restricted stock awards and unvested PSUs that were outstanding at March 31, 2022 vested on April 8, 2022. His remaining unvested time-vesting restricted stock awards and PSUs were forfeited on March 31, 2022. These payments, rights and benefits are substantially similar to the severance benefits contemplated by his previous employment agreement in respect to a termination without cause thereunder. In aggregate, we recognized a net $ 0 and $ 1,508 of expense in relation to Dr. Tang's stock compensation during the three and nine months ended September 30, 2022, respectively. On April 1, 2022 the Company's Board of Directors appointed Nancy J. Gagliano, M.D., M.B.A., to serve as the Company’s Interim Chief Executive Officer. In connection therewith, the Company and Dr. Gagliano entered into an employment agreement, dated as of March 21, 2022 (the “Employment Agreement”). Pursuant to the Employment Agreement, on April 1, 2022, Dr. Gagliano began receiving a monthly base salary of $ 56 per month and was also granted a one-time award of fully vested shares of the Company’s common stock with a grant date fair value of $ 100 . Additionally, she was granted a one-time restricted stock unit award with a grant date fair value of $ 670 scheduled to vest in twelve equal monthly installments starting in April through her employment term, of which $ 168 vested during the three months ended June 30, 2022 and the remainder was forfeited when her employment ceased in June 2022. On May 20, 2022, the Company entered into an employment agreement with Carrie Eglinton Manner, and in connection therewith, the Company's Board of Directors appointed Ms. Eglinton Manner as the Company’s President and Chief Executive Officer, effective June 4, 2022 (the “Effective Date”). Pursuant to the employment agreement, Ms. Eglinton Manner’s initial annual base salary is $ 700 and she will participate in the Company’s annual incentive plan with a target annual incentive amount of at least 100 % of her annual base salary. Additionally, she received inducement grants comprised of (i) a restricted stock unit award with a grant date fair value of $ 4,000 , which vests on the second anniversary of the Effective Date (ii) a restricted stock award with a grant date fair value of $ 1,600 , which vests annually starting on the first anniversary of the Effective Date and (iii) a PSU award, which will be subject to the same vesting and performance conditions as are applicable to the 2022 performance-based restricted stock unit awards granted to the Company’s other executive officers.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes During the three and nine months ended September 30, 2022 , we recorded an income tax expense (benefit) of $( 1,143 ) and $ 1,624 , respectively. Tax expense for the nine months ended September 30, 2022 includes $ 1,683 of withholding tax paid on the repatriation of $ 65,000 of unremitted earnings from Canada to the United States. The remaining tax expense for the first nine months of 2022 is comprised of U.S. state income taxes of $ 379 and a foreign tax benefit of $ 438 . During the three and nine months ended September 30, 2021 , we recorded income tax expense of $ 2,102 and $ 12,241 , respectively, which primarily consists of foreign tax expense. The decline in foreign tax expense in both periods of 2022 compared to 2021 is a result of the decrease in income before taxes generated by our Canadian subsidiary. Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2022 and December 31, 2021 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes along with basis differences arising from accelerated tax depreciation of fixed assets. In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both September 30, 2022 and December 31, 2021 since the facts and circumstances necessitating the allowance have not changed.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Litigation From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations. In March 2021, we filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum has filed an answer to the initial complaint, asserting that its device does not infringe our patent and that our patent is invalid. In August 2021, we amended our complaint to add a second patent to this litigation. Spectrum responded to our amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office. DNAG filed a motion to dismiss Spectrum’s counterclaims in October 2021, which was denied by the Court on March 30, 2022. Fact discovery is ongoing. The final pretrial conference is set for September 7, 2023.

Business Segment Information

Business Segment Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Business Segment Information	13. Business Segment Information Our business consists of two segments: our “Diagnostics” business, which primarily consists of the development, manufacture, and sale of rapid diagnostic tests used to determine if a person has a variety of infectious diseases including, HIV, HCV, and COVID-19. The Diagnostic business also manufactures and sells oral fluid substance abuse testing products. Our “Molecular Solutions” business is operated by our wholly-owned subsidiaries DNAG, Diversigen, and Novosanis. This segment of the business consists of the development, manufacture, and sale of kits that are used to collect, stabilize, transport and store a biological sample of genetic material for molecular testing. In addition, our Molecular Solutions business provides microbiome laboratory services. We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 1). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Inter-segment revenues and expenses are eliminated. The following table summarizes operating segment information for the three and nine months ended September 30, 2022 and 2021, and asset information as of September 30, 2022 and December 31, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net revenues: Diagnostics $ 97,651 $ 23,511 $ 196,416 $ 57,368 Molecular Solutions 18,812 30,406 67,985 112,738 Total $ 116,463 $ 53,917 $ 264,401 $ 170,106 Operating income (loss): Diagnostics $ 11,289 $ ( 18,446 ) $ ( 20,274 ) $ ( 42,413 ) Molecular Solutions ( 10,414 ) 5,433 ( 16,118 ) 41,620 Total $ 875 $ ( 13,013 ) $ ( 36,392 ) $ ( 793 ) Depreciation and amortization: Diagnostics $ 2,112 $ 1,136 $ 5,742 $ 2,965 Molecular Solutions 1,815 2,199 5,649 5,514 Total $ 3,927 $ 3,335 $ 11,391 $ 8,479 Loss on impairment: Diagnostics $ — $ — $ 8,517 $ — Molecular Solutions 6,559 — 8,584 — Total $ 6,559 $ — $ 17,101 $ — Capital expenditures: Diagnostics (1) $ 2,212 $ 3,647 $ 25,646 $ 19,797 Molecular Solutions 429 932 2,435 7,711 Total $ 2,641 $ 4,579 $ 28,081 $ 27,508 (1) Excludes $ 4,902 and $ 38,705 for purchases of property and equipment under government contracts for the three and nine months ended September 30, 2022, respectively. September 30, December 31, Total assets: Diagnostics $ 265,790 $ 209,674 Molecular Solutions 166,418 251,316 Total $ 432,208 $ 460,990

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation . The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results of operations expected for the full year. Summary of Significant Accounting Policies . There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that have had a material impact on the consolidated financial statements and related notes except as discussed herein.
Investments	Investments . We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds purchased with maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. During the nine months ended September 30, 2022, we recognized a provision for expected credit losses for our available-for-sale securities of $ 56 . The following is a summary of our available-for-sale securities as of September 30, 2022 and December 31, 2021: Amortized Gross Gross Fair Value September 30, 2022 Guaranteed investment certificates $ 21,688 $ — $ — $ 21,688 Corporate bonds 5,011 — ( 267 ) 4,744 Total available-for-sale securities $ 26,699 $ — $ ( 267 ) $ 26,432 December 31, 2021 Guaranteed investment certificates $ 33,249 $ — $ — $ 33,249 Corporate bonds 20,473 — ( 434 ) 20,039 Total available-for-sale securities $ 53,722 $ — $ ( 434 ) $ 53,288 At September 30, 2022, maturities of our available-for-sale Less than one year $ 26,699 $ — $ ( 267 ) $ 26,432 Greater than one year $ — $ — $ — $ —
Fair Value of Financial Instruments	Fair Value of Financial Instruments . As of September 30, 2022 and December 31, 2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale debt securities are measured as Level 2 instruments as of September 30, 2022 and December 31, 2021. Our available-for-sale guaranteed investment certificates are measured as Level 1 instruments as of September 30, 2022 and December 31, 2021. Included in cash and cash equivalents at September 30, 2022 and December 31, 2021, was $ 1,717 and $ 1,160 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of September 30, 2022 and December 31, 2021 was $ 1,599 and $ 1,763 , respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.
Property, Plant and Equipment	Property, Plant and Equipment . Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty years , while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years . Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of September 30, 2022 and December 31, 2021 was $ 68,626 and $ 61,157 , respectively.
Intangible Assets	Intangible Assets . Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years . Accumulated amortization of intangible assets as of September 30, 2022 and December 31, 2021 was $ 29,943 and $ 30,412 , respectively. The decrease in intangible assets from $ 14,343 as of December 31, 2021 to $ 11,919 as of September 30, 2022 was due to $ 1,617 in amortization expense and foreign currency translation losses of $ 807 .
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets . Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. We assess the recoverability of our long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. During the three months ended September 30, 2022, management determined several manufacturing lines and associated supporting assets will not be utilized due to changes in forecasted demand for the products the lines are intended to produce. As a result of this decision, we determined that the carrying values of the equipment is not recoverable and recorded an aggregate pre-tax asset impairment charge of $ 6,559 during the three months ended September 30, 2022 to write the assets down to their estimated fair values. This charge is reported within loss on impairment in the consolidated statement of operations. We estimated the fair value of the impaired long-lived assets using a market approach, which required us to estimate the value that would be received for the equipment in the most advantageous market for that equipment in an orderly transaction between market participants. Due to the extremely specialized nature of the manufacturing equipment and various market data points, the estimated fair value was not significant. Our fair value estimates were representative of Level 3 measurements within the fair value hierarchy due to the significant level of estimation involved and the lack of transparency as to the inputs used.
Foreign Currency Translation	Foreign Currency Translation . The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains resulting from foreign currency transactions that are included in other income in our consolidated statements of operations were $ 2,342 and $ 7 for the three months ended September 30, 2022 and 2021, respectively. Net foreign exchange gains (losses) were $ 2,396 and $( 371 ) f or the nine months ended September 30, 2022 and 2021 , respectively.
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Loss . We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at September 30, 2022 consisted of $ 22,064 of currency translation adjustments and $ 267 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2021 consists of $ 9,643 of currency translation adjustments and $ 434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio.
Recent Accounting Pronouncements	Recent Accounting Pronouncements . In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU were effective upon issuance and could be applied prospectively through December 31, 2022. The FASB issued a proposed amendment to the ASU in April 2022 which, if approved, will extend the date for prospective application to December 31, 2024. Management has evaluated this ASU and concluded that it will not have a material impact on the Company's Consolidated Financial Statements .
Revenues by Product	Revenues by product line . The following table represents total net revenues by product line: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 COVID-19 $ 79,920 $ 13,930 $ 154,331 $ 54,147 Genomics 13,980 19,018 44,558 49,333 HIV 9,054 10,022 27,577 29,745 HCV 3,234 2,715 10,182 9,382 Substance abuse 2,595 2,674 7,786 7,265 Microbiome 1,761 1,693 5,583 5,888 Laboratory services 1,957 2,406 4,895 8,017 Other product and service revenues 320 771 2,312 1,772 Net product and services revenues 112,821 53,229 257,224 165,549 Royalty income 409 500 1,735 2,636 Other non-product revenues* 3,233 188 5,442 1,921 Other revenues 3,642 688 7,177 4,557 Net revenues $ 116,463 $ 53,917 $ 264,401 $ 170,106 * Other non-product revenues include funded research and development under our BARDA contracts and other grant revenues.
Revenues by Geographic Area	Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 108,941 $ 42,969 $ 237,248 $ 139,669 Europe 2,207 2,411 8,929 10,288 Other regions 5,315 8,537 18,224 20,149 $ 116,463 $ 53,917 $ 264,401 $ 170,106
Customer and Vendor Concentrations	Customer and Vendor Concentrations . At September 30, 2022 , one non-commercial customer accounted for 47 % of our accounts receivable. No customers accounted for more than 10 % of our accounts receivable as of December 31, 2021 . One non-commercial customer accounted for 69 % and 53 % of net consolidated revenues for the three and nine months ended September 30, 2022 , respectively. One customer accounted for 14 % of net consolidated revenues for the three months ended September 30, 2021 . Another customer accounted for 10 % of net consolidated revenues for the nine months ended September 30, 2021. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Deferred Revenue	Deferred Revenue . We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2022 and December 31, 2021 includes customer prepayments of $ 1,762 and $ 1,843 , respectively. Deferred revenue as of September 30, 2022 and December 31, 2021 also include s $ 774 and $ 1,093 , respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Available-for-sale Securities	The following is a summary of our available-for-sale securities as of September 30, 2022 and December 31, 2021: Amortized Gross Gross Fair Value September 30, 2022 Guaranteed investment certificates $ 21,688 $ — $ — $ 21,688 Corporate bonds 5,011 — ( 267 ) 4,744 Total available-for-sale securities $ 26,699 $ — $ ( 267 ) $ 26,432 December 31, 2021 Guaranteed investment certificates $ 33,249 $ — $ — $ 33,249 Corporate bonds 20,473 — ( 434 ) 20,039 Total available-for-sale securities $ 53,722 $ — $ ( 434 ) $ 53,288 At September 30, 2022, maturities of our available-for-sale Less than one year $ 26,699 $ — $ ( 267 ) $ 26,432 Greater than one year $ — $ — $ — $ —

Government Capital Contracts (T

Government Capital Contracts (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Government Contracts Balances Included In Consolidated Balance Sheet	The balances corresponding to government contracts included in our consolidated balance sheet are as follows: September 30, 2022 December 31, 2021 Other current assets: Billed receivables $ 1,489 $ 9,913 Unbilled receivables 13,840 9,716 Total other current assets 15,329 19,629 Property, plant and equipment, net: Cost of assets, cumulative 50,200 11,495 Reduction for funding earned to date, not yet received ( 11,913 ) ( 10,964 ) Reduction for funding received to date ( 38,287 ) ( 531 ) Total property, plant and equipment, net — — Other non-current assets - unbilled receivables 2,489 — Accrued expenses and other current liabilities $ ( 404 ) $ ( 8,103 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories September 30, 2022 December 31, 2021 Raw materials $ 37,137 $ 33,168 Work in process 2,499 2,252 Finished goods 39,169 17,718 $ 78,805 $ 53,138

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Computations of Basic and Diluted Earnings (Loss) Per Share	The computations of basic and diluted earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net income (loss) $ 5,273 $ ( 15,015 ) $ ( 33,496 ) $ ( 12,605 ) Weighted-average shares of common stock outstanding: Basic 72,616 72,023 72,448 71,962 Dilutive effect of stock options, restricted stock, and performance stock units 169 — — — Diluted 72,785 72,023 72,448 71,962 Earnings (loss) per share: Basic $ 0.07 $ ( 0.21 ) $ ( 0.46 ) $ ( 0.18 ) Diluted $ 0.07 $ ( 0.21 ) $ ( 0.46 ) $ ( 0.18 )

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Product and Geographic Area	Revenues by product line . The following table represents total net revenues by product line: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 COVID-19 $ 79,920 $ 13,930 $ 154,331 $ 54,147 Genomics 13,980 19,018 44,558 49,333 HIV 9,054 10,022 27,577 29,745 HCV 3,234 2,715 10,182 9,382 Substance abuse 2,595 2,674 7,786 7,265 Microbiome 1,761 1,693 5,583 5,888 Laboratory services 1,957 2,406 4,895 8,017 Other product and service revenues 320 771 2,312 1,772 Net product and services revenues 112,821 53,229 257,224 165,549 Royalty income 409 500 1,735 2,636 Other non-product revenues* 3,233 188 5,442 1,921 Other revenues 3,642 688 7,177 4,557 Net revenues $ 116,463 $ 53,917 $ 264,401 $ 170,106 * Other non-product revenues include funded research and development under our BARDA contracts and other grant revenues. Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 108,941 $ 42,969 $ 237,248 $ 139,669 Europe 2,207 2,411 8,929 10,288 Other regions 5,315 8,537 18,224 20,149 $ 116,463 $ 53,917 $ 264,401 $ 170,106

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table represents the changes in goodwill by operating segment for the nine months ended September 30, 2022: Diagnostics Molecular Solutions Balance as of January 1, 2022 $ 3,604 $ 36,675 Impairment ( 3,604 ) — Change related to foreign currency translation — ( 2,199 ) Balance as of September 30, 2022 $ — $ 34,476

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	September 30, December 31, Payroll and related benefits $ 11,263 $ 15,570 Commitment to purchase under government contract — 8,103 Professional fees 4,771 3,335 Sales tax payable 1,372 2,227 Other 8,006 4,543 $ 25,412 $ 33,778

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Lessee Disclosure [Abstract]
Summary of Components of Lease Expense	The components of lease expense are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost $ 842 $ 655 $ 2,352 $ 1,574 Variable and short-term lease cost 332 — 559 — Finance lease cost: Amortization of right-of use assets 343 571 1,034 910 Interest on lease liabilities 19 49 74 84 Total finance lease cost 362 620 1,108 994 Total lease cost $ 1,536 $ 1,275 $ 4,019 $ 2,568
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows: Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 3,659 $ 1,182 Operating cash flows from financing leases 74 84 Financing cash flows from financing leases 826 1,111 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations 9,038 45 Right-of-use assets obtained in exchange for finance lease obligations 117 2,746
Summary of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: September 30, 2022 December 31, 2021 Operating Leases Right-of-use assets $ 15,769 $ 9,056 Lease liabilities: Current lease liabilities 1,938 2,181 Non-current lease liabilities 14,493 7,202 Total operating lease liabilities $ 16,431 $ 9,383 Finance Leases Right-of-use assets $ 1,590 $ 2,493 Lease liabilities: Current lease liabilities 1,242 939 Non-current lease liabilities 935 1,952 Total finance lease liabilities $ 2,177 $ 2,891
Summary of Lease Term and Discount Rate	Weighted Average Remaining Lease Term Weighted-average remaining lease term—operating leases 7.46 years 5.26 years Weighted-average remaining lease term—finance leases 1.59 years 2.21 years Weighted Average Discount Rate Weighted-average discount rate—operating leases 4.25 % 3.90 % Weighted-average discount rate—finance leases 3.45 % 3.57 %
Schedule of Minimum Lease Payments by Period Expected	As of September 30, 2022, minimum lease payments by period are expected to be as follows: Finance Operating 2022 (excluding the nine months ended September 30, 2022) $ 373 $ 795 2023 1,125 2,043 2024 738 2,947 2025 18 2,583 2026 11 2,385 Thereafter — 8,800 Total minimum lease payments 2,265 19,553 Less: imputed interest ( 88 ) ( 3,122 ) Present value of lease liabilities $ 2,177 $ 16,431

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Reconciliation of Changes in Stockholders' Equity	Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021 Common Stock Additional Accumulated Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2021 72,069 $ — $ 511,063 $ ( 10,077 ) $ ( 120,453 ) $ 380,533 Common stock issued upon exercise of options 2 — 15 — — 15 Vesting of restricted stock and performance stock units 352 — — — — — Purchase and retirement of common shares ( 116 ) — ( 1,049 ) — — ( 1,049 ) Stock-based compensation — — 3,524 — — 3,524 Net loss — — — — ( 19,967 ) ( 19,967 ) Currency translation adjustments — — — 1,756 — 1,756 Unrealized gain on marketable securities — — — 74 — 74 Balance at March 31, 2022 72,307 $ — $ 513,553 $ ( 8,247 ) $ ( 140,420 ) $ 364,886 Common stock issued upon exercise of options — — — — — — Vesting of restricted stock and performance stock units 407 — — — — — Purchase and retirement of common shares ( 142 ) — ( 905 ) — — ( 905 ) Stock-based compensation — — 3,280 — — 3,280 Net loss — — — — ( 18,802 ) ( 18,802 ) Currency translation adjustments — — — ( 4,349 ) — ( 4,349 ) Unrealized gain on marketable securities — — — 82 — 82 Balance at June 30, 2022 72,572 $ — $ 515,928 $ ( 12,514 ) $ ( 159,222 ) $ 344,192 Common stock issued upon exercise of options — — — — — — Vesting of restricted stock and performance stock units 66 — — — — — Purchase and retirement of common shares ( 19 ) — ( 54 ) — — ( 54 ) Stock-based compensation — — 2,296 — — 2,296 Net income — — — — 5,273 5,273 Currency translation adjustments — — — ( 9,828 ) — ( 9,828 ) Unrealized loss on marketable securities — — — 11 — 11 Balance at September 30, 2022 72,619 $ — $ 518,170 $ ( 22,331 ) $ ( 153,949 ) $ 341,890 Common Stock Additional Accumulated Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2020 71,738 $ — $ 505,123 $ ( 9,097 ) $ ( 97,455 ) $ 398,571 Common stock issued upon exercise of options 11 — 92 — — 92 Vesting of restricted stock and performance stock units 318 — — — — Purchase and retirement of common shares ( 111 ) — ( 1,730 ) — — ( 1,730 ) Stock-based compensation — — 1,464 — — 1,464 Net income — — — — 3,774 3,774 Currency translation adjustments — — — 1,352 — 1,352 Unrealized gain on marketable securities — — — 21 — 21 Balance at March 31, 2021 71,956 $ — $ 504,949 $ ( 7,724 ) $ ( 93,681 ) $ 403,544 Common stock issued upon exercise of options 3 — 29 — — 29 Vesting of restricted stock and performance stock units 64 — — — — — Purchase and retirement of common shares ( 15 ) — ( 147 ) — — ( 147 ) Stock-based compensation — — 1,473 — — 1,473 Net loss — — — — ( 1,364 ) ( 1,364 ) Currency translation adjustments — — — 1,403 — 1,403 Unrealized loss on marketable securities — — — ( 122 ) — ( 122 ) Balance at June 30, 2021 72,008 $ — $ 506,304 $ ( 6,443 ) $ ( 95,045 ) $ 404,816 Common stock issued upon exercise of options 18 — 126 — — 126 Vesting of restricted stock and performance stock units 16 — — — — — Purchase and retirement of common shares ( 4 ) — ( 47 ) — — ( 47 ) Stock-based compensation — — 2,218 — — 2,218 Net loss — — — — ( 15,015 ) ( 15,015 ) Currency translation adjustments — — — ( 4,117 ) — ( 4,117 ) Unrealized loss on marketable securities — — — ( 161 ) — ( 161 ) Balance at September 30, 2021 72,038 $ — $ 508,601 $ ( 10,721 ) $ ( 110,060 ) $ 387,820
Summary of Company's Stock Option Activity	The following table summarizes the stock option activity for the nine months ended September 30, 2022: Options Outstanding on January 1, 2022 1,410 Granted 589 Exercised ( 2 ) Expired ( 20 ) Forfeited ( 173 ) Outstanding on September 30, 2022 1,804
Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity	The following table summarizes time-vested restricted stock award and restricted stock unit activity for the nine months ended September 30, 2022: Units Issued and unvested, January 1, 2022 701 Granted 2,964 Vested ( 618 ) Forfeited ( 270 ) Issued and unvested, September 30, 2022 2,777
Performance Based Restricted Stock Unit [Member]
Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan	The following table summarizes the PSU activity for the nine months ended September 30, 2022: Units Issued and unvested, January 1, 2022 622 Granted (1) 532 Performance adjustment (2) 36 Vested ( 207 ) Forfeited ( 200 ) Issued and unvested, September 30, 2022 783 (1) Grant activity for all PSUs disclosed at target (2) Reflects the performance adjustment based on actual performance measured at the end of the performance period

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Operating Segment and Asset Information	The following table summarizes operating segment information for the three and nine months ended September 30, 2022 and 2021, and asset information as of September 30, 2022 and December 31, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net revenues: Diagnostics $ 97,651 $ 23,511 $ 196,416 $ 57,368 Molecular Solutions 18,812 30,406 67,985 112,738 Total $ 116,463 $ 53,917 $ 264,401 $ 170,106 Operating income (loss): Diagnostics $ 11,289 $ ( 18,446 ) $ ( 20,274 ) $ ( 42,413 ) Molecular Solutions ( 10,414 ) 5,433 ( 16,118 ) 41,620 Total $ 875 $ ( 13,013 ) $ ( 36,392 ) $ ( 793 ) Depreciation and amortization: Diagnostics $ 2,112 $ 1,136 $ 5,742 $ 2,965 Molecular Solutions 1,815 2,199 5,649 5,514 Total $ 3,927 $ 3,335 $ 11,391 $ 8,479 Loss on impairment: Diagnostics $ — $ — $ 8,517 $ — Molecular Solutions 6,559 — 8,584 — Total $ 6,559 $ — $ 17,101 $ — Capital expenditures: Diagnostics (1) $ 2,212 $ 3,647 $ 25,646 $ 19,797 Molecular Solutions 429 932 2,435 7,711 Total $ 2,641 $ 4,579 $ 28,081 $ 27,508 (1) Excludes $ 4,902 and $ 38,705 for purchases of property and equipment under government contracts for the three and nine months ended September 30, 2022, respectively. September 30, December 31, Total assets: Diagnostics $ 265,790 $ 209,674 Molecular Solutions 166,418 251,316 Total $ 432,208 $ 460,990

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 26,699	$ 53,722
Gross Unrealized Losses	(267)	(434)
Fair Value	26,432	53,288
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	21,688	33,249
Fair Value	21,688	33,249
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	5,011	20,473
Gross Unrealized Losses	(267)	(434)
Fair Value	4,744	$ 20,039
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	26,699
Gross Unrealized Losses	(267)
Fair Value	$ 26,432

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 75,205		$ 75,205		$ 116,762
Fair value of plan assets	1,599		1,599		1,763
Accumulated depreciation of property and equipment	68,626		68,626		61,157
Accumulated amortization of intangible assets	29,943		29,943		30,412
Intangible Assets, Net	11,919		11,919		14,343
Intangible Assets, amortization expense			1,617
Intangible Assets, Foreign currency translation losses			807
Pre-tax asset impairment charge	6,559
Credit losses	56		56
Net foreign exchange gains (losses)	2,342	$ 7	2,396	$ (371)
Accumulated foreign currency adjustments included in other comprehensive loss amounted	22,064		22,064		9,643
Unrealized loss on marketable securities	267		$ 267		434
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)			5 years
Minimum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Minimum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Minimum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)			15 years
Maximum [Member] | Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			20 years
Maximum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Maximum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Maximum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets			10 years
Money Market Fund [Member] | Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 1,717		$ 1,717		$ 1,160

Government Capital Contracts -

Government Capital Contracts - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government capital contracts funding amount		$ 109,000		$ 109,000
Percentage withheld under government contracts subject to validation testing	15%		15%
Proceeds from funding under government contract			$ 37,756		$ 531
Net revenues	$ 116,463	$ 53,917	264,401	$ 170,106
Government Contract [Member] | Other Income (Loss) [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	$ 561		$ 1,684

Government Capital Contracts _2

Government Capital Contracts - Summary Of Government Contracts Balances Included In Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total other current assets	$ 32,140	$ 28,990
Property, Plant and Equipment [Abstract]
Total property, plant and equipment, net	85,184	88,164
Accrued expenses and other current liabilities	25,412	33,778
Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Billed receivables	1,489	9,913
Unbilled receivables	13,840	9,716
Total other current assets	15,329	19,629
Property, Plant and Equipment [Abstract]
Cost of assets, cumulative	50,200	11,495
Reduction for funding earned to date, not yet received	(11,913)	(10,964)
Reduction for funding received to date	(38,287)	(531)
Total property, plant and equipment, net		0
Other non-current assets - unbilled receivables	2,489
Accrued expenses and other current liabilities	$ (404)	$ (8,103)

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory, Net [Abstract]
Raw materials	$ 37,137	$ 33,168
Work in process	2,499	2,252
Finished goods	39,169	17,718
Inventories	$ 78,805	$ 53,138

Earnings (Loss) Per Share - Com

Earnings (Loss) Per Share - Computations of Basic and Diluted Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net income (loss)	$ 5,273	$ (18,802)	$ (19,967)	$ (15,015)	$ (1,364)	$ 3,774	$ (33,496)	$ (12,605)
Weighted-average shares of common stock outstanding:
Basic	72,616			72,023			72,448	71,962
Dilutive effect of stock options, restricted stock, and performance stock units	169
Diluted	72,785			72,023			72,448	71,962
Basic	$ 0.07			$ (0.21)			$ (0.46)	$ (0.18)
Diluted	$ 0.07			$ (0.21)			$ (0.46)	$ (0.18)

Earnings (Loss) Per Share - Add

Earnings (Loss) Per Share - Additional Information (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Number of anti-dilutive securities excluded from EPS computation	1,734	859	383	847

Revenues - Summary of Total Net

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Net revenues		$ 116,463	$ 53,917	$ 264,401	$ 170,106
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		112,821	53,229	257,224	165,549
Product and Services Revenues [Member] | COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		79,920	13,930	154,331	54,147
Product and Services Revenues [Member] | Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		13,980	19,018	44,558	49,333
Product and Services Revenues [Member] | HIV [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		9,054	10,022	27,577	29,745
Product and Services Revenues [Member] | HCV [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		3,234	2,715	10,182	9,382
Product and Services Revenues [Member] | Substance Abuse [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		2,595	2,674	7,786	7,265
Product and Services Revenues [Member] | Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		1,761	1,693	5,583	5,888
Product and Services Revenues [Member] | Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		1,957	2,406	4,895	8,017
Product and Services Revenues [Member] | Other Product and Service Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		320	771	2,312	1,772
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		3,642	688	7,177	4,557
Other [Member] | Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		409	500	1,735	2,636
Other [Member] | Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	[1]	$ 3,233	$ 188	$ 5,442	$ 1,921
[1] Other non-product revenues include funded research and development under our BARDA contracts and other grant revenues.

Revenues - Summary of Total N_2

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Net revenues	$ 116,463	$ 53,917	$ 264,401	$ 170,106
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	108,941	42,969	237,248	139,669
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,207	2,411	8,929	10,288
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 5,315	$ 8,537	$ 18,224	$ 20,149

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenue from contract with customer [Line Items]
Deferred revenue	$ 2,536		$ 2,536		$ 2,936
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	774		774		1,093
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 1,762		$ 1,762		$ 1,843
Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Maximum [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk					10%
Customer [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk		14%
Non-commercial Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk			47%
Non-commercial Customer One [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	69%		53%
Customer Two [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk				10%

Goodwill - Schedule of Goodwill

Goodwill - Schedule of Goodwill by Operating Segment (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill [Line Items]
Beginning Balance	$ 40,279
Ending Balance	34,476
Diagnostics [Member]
Goodwill [Line Items]
Beginning Balance	3,604
Impairment	(3,604)
Molecular Solutions [Member]
Goodwill [Line Items]
Beginning Balance	36,675
Change related to foreign currency translation	(2,199)
Ending Balance	$ 34,476

Goodwill - Additional Informati

Goodwill - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Diagnostics [Member]
Goodwill [Line Items]
Pre-tax impairment charge	$ 3,604
Discount rate used for income approach	22%
Molecular Solutions [Member]
Goodwill [Line Items]
Discount rate used for income approach	20%
Market-Based Approach [Member]
Goodwill [Line Items]
Weight applied to valuation approach	25%
Income-Based Approach [Member]
Goodwill [Line Items]
Weight applied to valuation approach	75%

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 11,263	$ 15,570
Commitment to purchase under government contract		8,103
Professional fees	4,771	3,335
Sales tax payable	1,372	2,227
Other	8,006	4,543
Accrued expenses and other current liabilities	$ 25,412	$ 33,778

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands		9 Months Ended
	Oct. 19, 2022 USD ($)	Sep. 30, 2022	Jan. 03, 2022 ft²
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate		true
Lessee operating and financing leases, period of options to terminate		1 year
Lessee, operating and finance lease, existence of option to extend		true
Warehouse Agreement [Member]
Lessee Lease Description [Line Items]
Area of facility | ft²			96,010
Subsequent Event [Member] | Warehouse Agreement [Member]
Lessee Lease Description [Line Items]
Lease termination effective date	Oct. 31, 2022
Annual cash savings on lease termination	$ 735
Reduction in operating right-of-use assets	4,927
Reduction in operating lease liabilities	$ 5,146
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms		1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms		11 years

Leases - Summary of Components

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lease, Cost [Abstract]
Operating lease cost	$ 842	$ 655	$ 2,352	$ 1,574
Variable and short-term lease cost	332		559
Finance Lease Cost
Amortization of right-of use assets	343	571	1,034	910
Interest on lease liabilities	19	49	74	84
Total finance lease cost	362	620	1,108	994
Total lease cost	$ 1,536	$ 1,275	$ 4,019	$ 2,568

Leases - Summary of Supplementa

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 3,659	$ 1,182
Operating cash flows from financing leases	74	84
Financing cash flows from financing leases	826	1,111
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	9,038	45
Right-of-use assets obtained in exchange for finance lease obligations	$ 117	$ 2,746

Leases - Summary of Supplemen_2

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Operating Leases
Right-of-use assets	$ 15,769	$ 9,056
Lease liabilities:
Current lease liabilities	1,938	2,181
Non-current lease liabilities	14,493	7,202
Total operating lease liabilities	16,431	9,383
Finance Leases
Right-of-use assets	1,590	2,493
Lease liabilities:
Current lease liabilities	1,242	939
Non-current lease liabilities	935	1,952
Total finance lease liabilities	$ 2,177	$ 2,891

Leases - Summary of Lease Term

Leases - Summary of Lease Term and Discount Rate (Detail)	Sep. 30, 2022	Dec. 31, 2021
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	7 years 5 months 15 days	5 years 3 months 3 days
Weighted-average remaining lease term—finance leases	1 year 7 months 2 days	2 years 2 months 15 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.25%	3.90%
Weighted-average discount rate—finance leases	3.45%	3.57%

Leases - Schedule of Minimum Le

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finance Lease Liabilities, Payments, Due [Abstract]
2022 (excluding the six months ended June 30, 2022)	$ 373
2023	1,125
2024	738
2025	18
2026	11
Total minimum finance lease payments	2,265
Less: imputed interest	(88)
Present value of finance lease liabilities	2,177	$ 2,891
Operating Lease Liabilities, Payments Due [Abstract]
2022 (excluding the six months ended June 30, 2022)	795
2023	2,043
2024	2,947
2025	2,583
2026	2,385
Thereafter	8,800
Total minimum operating Lease Payments	19,553
Less: imputed interest	(3,122)
Present value of operating lease liabilities	$ 16,431	$ 9,383

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Beginning Balance	$ 344,192	$ 364,886	$ 380,533	$ 404,816	$ 403,544	$ 398,571	$ 380,533	$ 398,571
Common stock issued upon exercise of options			15	126	29	92
Exercised							2,000
Purchase and retirement of common shares	(54)	(905)	(1,049)	(47)	(147)	(1,730)
Stock-based compensation	2,296	3,280	3,524	2,218	1,473	1,464
Net income (loss)	5,273	(18,802)	(19,967)	(15,015)	(1,364)	3,774	$ (33,496)	(12,605)
Currency translation adjustments	(9,828)	(4,349)	1,756	(4,117)	1,403	1,352	(12,421)	(1,362)
Unrealized gain (loss) on marketable securities	11	82	74	(161)	(122)	21	167	(262)
Ending Balance	$ 341,890	$ 344,192	$ 364,886	$ 387,820	$ 404,816	$ 403,544	$ 341,890	$ 387,820
Common Stock [Member]
Beginning Balance, Shares	72,572,000	72,307,000	72,069,000	72,008,000	71,956,000	71,738,000	72,069,000	71,738,000
Exercised			2,000	18,000	3,000	11,000
Vesting of restricted stock and performance stock units, Shares	66,000	407,000	352,000	16,000	64,000	318,000
Purchase and retirement of common shares, Shares	(19,000)	(142,000)	(116,000)	(4,000)	(15,000)	(111,000)
Ending Balance, Shares	72,619,000	72,572,000	72,307,000	72,038,000	72,008,000	71,956,000	72,619,000	72,038,000
Additional Paid-in Capital [Member]
Beginning Balance	$ 515,928	$ 513,553	$ 511,063	$ 506,304	$ 504,949	$ 505,123	$ 511,063	$ 505,123
Common stock issued upon exercise of options			15	126	29	92
Purchase and retirement of common shares	(54)	(905)	(1,049)	(47)	(147)	(1,730)
Stock-based compensation	2,296	3,280	3,524	2,218	1,473	1,464
Ending Balance	518,170	515,928	513,553	508,601	506,304	504,949	518,170	508,601
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(12,514)	(8,247)	(10,077)	(6,443)	(7,724)	(9,097)	(10,077)	(9,097)
Currency translation adjustments	(9,828)	(4,349)	1,756	(4,117)	1,403	1,352
Unrealized gain (loss) on marketable securities	11	82	74	(161)	(122)	21
Ending Balance	(22,331)	(12,514)	(8,247)	(10,721)	(6,443)	(7,724)	(22,331)	(10,721)
Accumulated Deficit [Member]
Beginning Balance	(159,222)	(140,420)	(120,453)	(95,045)	(93,681)	(97,455)	(120,453)	(97,455)
Net income (loss)	5,273	(18,802)	(19,967)	(15,015)	(1,364)	3,774
Ending Balance	$ (153,949)	$ (159,222)	$ (140,420)	$ (110,060)	$ (95,045)	$ (93,681)	$ (153,949)	$ (110,060)

Stockholders Equity - Summary o

Stockholders Equity - Summary of Company's Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Outstanding on January 1, 2022	1,410,000
Options, Granted	589,000
Options, Exercised	(2,000)
Options, Expired	(20,000)
Options, Forfeited	(173,000)
Outstanding on September 30, 2022	1,804,000

Stockholders Equity - ummary of

Stockholders Equity - ummary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award And Restricted Stock Units [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issued and unvested, January 1, 2022	701
Granted	2,964
Vested	(618)
Forfeited	(270)
Issued and unvested, September 30, 2022	2,777

Stockholders Equity - Summary_2

Stockholders Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Details) - Performance Based Restricted Stock Unit [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issued and unvested, January 1, 2022	622
Granted	532	[1]
Performance adjustment	36	[2]
Vested	(207)
Forfeited	(200)
Issued and unvested, September 30, 2022	783
[1] (1) Grant activity for all PSUs disclosed at target (2) Reflects the performance adjustment based on actual performance measured at the end of the performance period

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 9,100,000	$ 5,155,000
Amount share repurchase program of common shares			$ 25,000,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	1,213,000	793,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	7,047,000	2,891,000
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 840,000	$ 1,471,000
Performance Based Restricted Stock Unit [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock Unit [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0

Transition Costs - Additional I

Transition Costs - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended
	May 20, 2022	Apr. 01, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Transition Costs [Line Items]
Severance accrual							$ 1,569,000
Stock-based compensation					$ 9,100,000	$ 5,155,000
Restricted Stock [Member]
Transition Costs [Line Items]
Stock-based compensation					7,047,000	$ 2,891,000
Employment Agreement [Member] | Interim Chief Executive Officer [Member]
Transition Costs [Line Items]
Officer's compensation		$ 56,000
Common stock grant date fair value		100,000
Employment Agreement [Member] | Interim Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]
Transition Costs [Line Items]
Common stock grant date fair value		$ 670,000
One-time restricted stock unit award vested				$ 168,000
Employment Agreement [Member] | President And Chief Executive Officer [Member]
Transition Costs [Line Items]
Officer's compensation	$ 700,000
Target annual bonus percentage	100%
Employment Agreement [Member] | President And Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]
Transition Costs [Line Items]
Common stock grant date fair value	$ 4,000,000
Employment Agreement [Member] | President And Chief Executive Officer [Member] | Restricted Stock [Member]
Transition Costs [Line Items]
Common stock grant date fair value	$ 1,600,000
Transition costs [Member]
Transition Costs [Line Items]
Stock-based compensation			$ 0		$ 1,508,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (1,143)	$ 2,102	$ 1,624	$ 12,241
Withholding tax paid on the repatriation			1,683
Foreign earnings repatriated			65,000
State income tax expense			379
Foreign tax benefit			$ 438

Business Segment Information -

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information _2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenues	$ 116,463	$ 53,917	$ 264,401	$ 170,106
Operating income (loss)	875	(13,013)	(36,392)	(793)
Depreciation and amortization	3,927	3,335	11,391	8,479
Loss on impairment	6,559		17,101
Capital expenditures	2,641	4,579	28,081	27,508
Total assets	432,208		432,208		$ 460,990
Purchase Of Property And Equipment	4,902		38,705
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	97,651	23,511	196,416	57,368
Operating income (loss)	11,289	(18,446)	(20,274)	(42,413)
Depreciation and amortization	2,112	1,136	5,742	2,965
Loss on impairment			8,517
Capital expenditures	2,212	3,647	25,646	19,797
Total assets	265,790		265,790		209,674
Molecular Solutions [Member]
Segment Reporting Information [Line Items]
Net revenues	18,812	30,406	67,985	112,738
Operating income (loss)	(10,414)	5,433	(16,118)	41,620
Depreciation and amortization	1,815	2,199	5,649	5,514
Loss on impairment	6,559		8,584
Capital expenditures	429	$ 932	2,435	$ 7,711
Total assets	$ 166,418		$ 166,418		$ 251,316